Investing.com -- Novo Nordisk (NYSE: NVO) plans to sell its weight-loss drugs through the telehealth platform of Hims & Hers Health (NYSE: HIMS), marking a surprising reconciliation between the two companies after a recent legal dispute, Bloomberg reported over the weekend.

Shares of Hims, which have plunged about 51% this year, rocketed more than 44% in premarket trading Monday by 09:08 GMT, while Novo’s shares in Copenhagen climbed around 1%.

The companies could announce a new partnership as soon as Monday, the report said. The agreement would allow Novo’s obesity treatments to be offered on Hims’ platform, reviving a relationship that collapsed last year after Novo accused the telehealth company of continuing to market compounded versions of its drugs.

The renewed cooperation comes after tensions escalated earlier this year. Novo had sued Hims in February following the launch of a copycat version of its oral Wegovy weight-loss pill, arguing the product infringed patents tied to the active ingredient used in its blockbuster medications Ozempic and Wegovy.

Leerink analyst Michael Cherny described the development as “both a surprise and an unabashed positive for HIMS’ stock,” adding that it may prevent what had looked like “a protracted legal process that could include a full trial.”

Still, "even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential and thus maintain our Market Perform rating," Cherny wrote.

In a separate note, Morgan Stanley analyst Craig Hettenbach also said a new partnership could ease one of the biggest overhangs on the stock - regulatory and legal risks tied to the company’s weight-loss business. He stressed that “any reduction in those risks could lead to a strong rebound in the heavily shorted stock.”

Telehealth companies such as Hims sold lower-cost copies of Novo and Lilly weight-loss drugs during recent supply shortages. Although those shortages have ended and companies were expected to stop selling the copies, some have continued by modifying dosages or ingredients to differentiate them from branded drugs, the report said.